| 000 | 01749 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515162523.0 | ||
| 264 | 0 | _c20091009 | |
| 008 | 200910s 0 0 eng d | ||
| 022 | _a1554-8619 | ||
| 024 | 7 |
_a10.4161/hv.5.4.7050 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBojang, Kalifa | |
| 245 | 0 | 0 |
_aFive-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. _h[electronic resource] |
| 260 |
_bHuman vaccines _cApr 2009 |
||
| 300 |
_a242-7 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Protozoan _xblood |
| 650 | 0 | 4 |
_aAntigens, Protozoan _ximmunology |
| 650 | 0 | 4 |
_aEndemic Diseases _xprevention & control |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGambia _xepidemiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMalaria Vaccines _xadverse effects |
| 650 | 0 | 4 |
_aMalaria, Falciparum _xepidemiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPlasmodium falciparum _ximmunology |
| 650 | 0 | 4 |
_aRabies Vaccines _xadverse effects |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aMilligan, Paul | |
| 700 | 1 | _aPinder, Margaret | |
| 700 | 1 | _aDoherty, Tom | |
| 700 | 1 | _aLeach, Amanda | |
| 700 | 1 | _aOfori-Anyinam, Opokua | |
| 700 | 1 | _aLievens, Marc | |
| 700 | 1 | _aKester, Kent | |
| 700 | 1 | _aSchaecher, Kurt | |
| 700 | 1 | _aBallou, W Ripley | |
| 700 | 1 | _aCohen, Joe | |
| 773 | 0 |
_tHuman vaccines _gvol. 5 _gno. 4 _gp. 242-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4161/hv.5.4.7050 _zAvailable from publisher's website |
| 999 |
_c18716374 _d18716374 |
||